Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Recommendation of “Moderate Buy” by Analysts

Roivant Sciences Ltd. (NASDAQ:ROIV) has received an average rating of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $17.69.

A number of equities analysts have recently issued reports on the company. Bank of America raised their price target on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research note on Wednesday, September 11th. HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research report on Wednesday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th.

Roivant Sciences Stock Performance

Shares of Roivant Sciences stock opened at $11.95 on Thursday. Roivant Sciences has a 12 month low of $8.56 and a 12 month high of $13.06. The company has a current ratio of 27.91, a quick ratio of 27.91 and a debt-to-equity ratio of 0.05. The business has a fifty day simple moving average of $11.78 and a two-hundred day simple moving average of $11.31. The firm has a market capitalization of $8.84 billion, a P/E ratio of 2.12 and a beta of 1.24.

Roivant Sciences (NASDAQ:ROIV) last released its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.10). The business had revenue of $4.48 million for the quarter, compared to analysts’ expectations of $34.57 million. Roivant Sciences had a net margin of 3,827.42% and a negative return on equity of 14.65%. On average, equities analysts forecast that Roivant Sciences will post -1.14 earnings per share for the current fiscal year.

Insider Activity

In other Roivant Sciences news, Director Financial Lp Qvt sold 876,000 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total value of $10,354,320.00. Following the completion of the transaction, the director now directly owns 22,179,358 shares in the company, valued at $262,160,011.56. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other Roivant Sciences news, Director Financial Lp Qvt sold 876,000 shares of the firm’s stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $11.82, for a total transaction of $10,354,320.00. Following the sale, the director now directly owns 22,179,358 shares of the company’s stock, valued at $262,160,011.56. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew Gline sold 1,983,257 shares of the business’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.79, for a total value of $23,382,600.03. Following the completion of the transaction, the chief executive officer now owns 17,870,543 shares in the company, valued at $210,693,701.97. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 3,577,309 shares of company stock valued at $42,151,184 in the last ninety days. Corporate insiders own 7.90% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Rubric Capital Management LP raised its stake in Roivant Sciences by 15.0% during the second quarter. Rubric Capital Management LP now owns 23,000,000 shares of the company’s stock valued at $243,110,000 after purchasing an additional 3,000,000 shares in the last quarter. Troluce Capital Advisors LLC bought a new stake in shares of Roivant Sciences in the 2nd quarter worth about $31,182,000. FMR LLC raised its position in shares of Roivant Sciences by 5.6% during the 3rd quarter. FMR LLC now owns 49,145,056 shares of the company’s stock valued at $567,134,000 after buying an additional 2,593,910 shares in the last quarter. Clearbridge Investments LLC bought a new position in shares of Roivant Sciences in the 1st quarter valued at about $12,962,000. Finally, BlackBarn Capital Partners LP grew its position in Roivant Sciences by 63.1% in the second quarter. BlackBarn Capital Partners LP now owns 3,100,000 shares of the company’s stock worth $32,767,000 after acquiring an additional 1,199,406 shares in the last quarter. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.